Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray
Provided by
Dow Jones
By Chris Wack
Amneal Pharmaceuticals shares were up 9% after the Food and Drug Administration approved an abbreviated new drug application for over-the-counter Naloxone Hydrochloride nasal spray.
The stock, trading at $5.89 midday, hit its 52-week high of $6.46 on March 19.
The New Jersey-based pharmaceutical company said its Naloxone HCI nasal spray is a generic equivalent to OTC NARCAN HCI nasal spray, a medication used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.
The FDA approval means that Naloxone is now available for purchase.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 24, 2024 12:34 ET (16:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom